Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b.

Antiviral therapy - 1 Jan 2014

McPhee Fiona, Hernandez Dennis, Zhou Nannan, Yu Fei, Ueland Joseph, Monikowski Aaron, Chayama Kazuaki, Toyota Joji, Izumi Namiki, Yokosuka Osamu, Kawada Norifumi, Osaki Yukio, Hughes Eric A, Watanabe Hideaki, Ishikawa Hiroki, Kumada Hiromitsu

Abstract excerpt

BACKGROUND: Daclatasvir (DCV; BMS-790052) is a picomolar inhibitor of HCV non-structural protein 5A (NS5A) and has demonstrated efficacy in patients chronically infected with HCV. METHODS: In the double-blind, randomized studies AI444021 and AI444022, 71 Japanese patients chronically infected with HCV genotype 1 (predominantly genotype 1b) received DCV (10 mg or 60 mg) plus peginterferon alfa-2b or alfa-2a and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Imidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon alpha-2

Share to Interferons

Share to Interleukins

Share to Polyethylene Glycols

Share to Pyrrolidines

Share to Valine

Source

Identifiers

PMID: 24448487
DOI: 10.3851/IMP2729

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b.PMID 24448487Read ↗

Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir.Semantic proximity Read ↗

Pooled analysis of HCV genotype 1 resistance-associated substitutions in NS5A, NS3 and NS5B pre-and post-treatment with 12 weeks of daclatasvir, asunaprevir and beclabuvir.Semantic proximity Read ↗

Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens.Semantic proximity Read ↗

Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy.Semantic proximity Read ↗

Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir.Semantic proximity Read ↗

Mechanisms of Virologic Failure with Direct-Acting Antivirals in Hepatitis C and Strategies for Retreatment.Semantic proximity Read ↗

Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non-target sites, for DAA-based treatment and retreatment outcome.Semantic proximity Read ↗

Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b.Semantic proximity Read ↗

Resistance to direct antiviral agents in patients with hepatitis C virus infection.Semantic proximity Read ↗

Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1.Semantic proximity Read ↗

Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.Semantic proximity Read ↗

Emergence and Persistence of Resistance-Associated Substitutions in HCV GT3 Patients Failing Direct-Acting AntiviralsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.